Pfizer: FDA approves treatment for lymphoma

(CercleFinance.com) - The U.
S. Food and Drug Administration (FDA) approves Pfizer's ADCETRIS® combination regimen for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Approval is based on positive data from the Phase 3 ECHELON-3 trial, which demonstrated that the ADCETRIS regimen reduced the risk of death by 37%, a statistically significant and clinically meaningful improvement in overall survival (OS), compared with lenalidomide and rituximab plus placebo.

LBCL is a type of non-Hodgkin's lymphoma (NHL), which affects immune cells called B lymphocytes, a type of white blood cell crucial to the body's immune system. LDGCB is the most common, aggressive and difficult-to-treat form of the disease.

' Today's approval further strengthens ADCETRIS' important role as an existing standard of care with demonstrated improvement in overall survival for certain types of lymphoma, and now gives physicians an option beyond chemotherapy or CAR-T for patients with relapsed/refractory large B-cell lymphoma. said Roger Dansey, M.D., Pfizer's Head of Oncology.

Copyright (c) 2025 CercleFinance.com. All rights reserved.